Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders
SM Stanford, N Bottini - Nature Reviews Drug Discovery, 2023 - nature.com
Protein phosphatases act as key regulators of multiple important cellular processes and are
attractive therapeutic targets for various diseases. Although extensive effort has been …
attractive therapeutic targets for various diseases. Although extensive effort has been …
Strategies to enhance CAR-T persistence
Y Liu, L An, R Huang, J Xiong, H Yang, X Wang… - Biomarker …, 2022 - Springer
Chimeric antigen receptor T (CAR-T) cell therapy has significantly improved the life
expectancy for patients with refractory or relapse B cell lymphoma. As for B cell acute …
expectancy for patients with refractory or relapse B cell lymphoma. As for B cell acute …
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
CK Baumgartner, H Ebrahimi-Nik, A Iracheta-Vellve… - Nature, 2023 - nature.com
Immune checkpoint blockade is effective for some patients with cancer, but most are
refractory to current immunotherapies and new approaches are needed to overcome …
refractory to current immunotherapies and new approaches are needed to overcome …
A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity
The inhibition of protein tyrosine phosphatases 1B (PTP1B) and N2 (PTPN2) has emerged
as an exciting approach for bolstering T cell anti-tumor immunity. ABBV-CLS-484 is a …
as an exciting approach for bolstering T cell anti-tumor immunity. ABBV-CLS-484 is a …
Mapping spatial organization and genetic cell-state regulators to target immune evasion in ovarian cancer
The drivers of immune evasion are not entirely clear, limiting the success of cancer
immunotherapies. Here we applied single-cell spatial and perturbational transcriptomics to …
immunotherapies. Here we applied single-cell spatial and perturbational transcriptomics to …
Small molecule degraders of protein tyrosine phosphatase 1B and T‐cell protein tyrosine phosphatase for cancer immunotherapy
Protein tyrosine phosphatase 1B (PTP1B) and T‐cell protein tyrosine phosphatase (TC‐
PTP) play non‐redundant negative regulatory roles in T‐cell activation, tumor antigen …
PTP) play non‐redundant negative regulatory roles in T‐cell activation, tumor antigen …
X-CHIME enables combinatorial, inducible, lineage-specific and sequential knockout of genes in the immune system
MW LaFleur, AM Lemmen, ISL Streeter… - Nature …, 2024 - nature.com
Annotation of immunologic gene function in vivo typically requires the generation of
knockout mice, which is time consuming and low throughput. We previously developed …
knockout mice, which is time consuming and low throughput. We previously developed …
[HTML][HTML] The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells
IL-15 is under clinical investigation toward the goal of curing HIV infection because of its
abilities to reverse HIV latency and enhance immune effector function. However, increased …
abilities to reverse HIV latency and enhance immune effector function. However, increased …
[HTML][HTML] PTP1B inhibitors protect against acute lung injury and regulate CXCR4 signaling in neutrophils
Acute lung injury (ALI) can cause acute respiratory distress syndrome (ARDS), a lethal
condition with limited treatment options and currently a common global cause of death due …
condition with limited treatment options and currently a common global cause of death due …
CRISPR/Cas9: A powerful strategy to improve CAR-T cell persistence
W Wei, ZN Chen, K Wang - International Journal of Molecular Sciences, 2023 - mdpi.com
As an emerging treatment strategy for malignant tumors, chimeric antigen receptor T (CAR-
T) cell therapy has been widely used in clinical practice, and its efficacy has been markedly …
T) cell therapy has been widely used in clinical practice, and its efficacy has been markedly …